RT Journal
A1 Leach R, Thompson IM
T1 THe dilemma of prostate-specific antigen testing
JF Archives of Internal Medicine
JO Archives of Internal Medicine
YR 2012
FD June 11
VO 172
IS 11
SP 835
OP 836
DO 10.1001/archinternmed.2012.1226
UL http://dx.doi.org/10.1001/archinternmed.2012.1226
AB 
For a man with prostate cancer, treatment decision making is daunting. If the tumor is high grade, decision making may be straightforward because disease-specific mortality is high despite the toxicity of combined therapies that are proved to reduce mortality (eg, radiation and hormonal therapy).1 For a man with an aggressive tumor, while decision making requires considerable thought, information, and support by the treating physician, the possibility of adverse effects often dims when there is an opportunity to improve survival.